# Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

> clinical trial · VERIFIED · 2026-07-16

Status: COMPLETED · Sponsor: Pierre Fabre Medicament · Condition: BRAF V600E-mutant Metastatic Colorectal Cancer

- Company: Pierre Fabre Medicament
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT03693170

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.